Clinical Trial

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-13; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06781333
Lead Sponsor Bernard (Barry) Baumel
Conditions Alzheimer Disease, Agitation in Dementia
Enrollment 8 participants
Start Date 2025-04-29
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-28